Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Clin Transl Oncol ; 20(10): 1280-1288, 2018 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-29594944

RESUMEN

PURPOSE: Capecitabine has been studied as a radiosensitizer, and our study seeks to examine the association of concurrent capecitabine/radiation therapy (RT) on event-free- (EFS) and overall survival (OS) in women with breast cancer (BC) with residual disease after neoadjuvant chemotherapy (NAC). METHODS/PATIENTS: In a retrospective study of women with BC who received adriamycin/taxane-based NAC from 2004-2016, we identified 21 women administered concurrent capecitabine/RT. To assess differences in survival, we selected a clinical control cohort (n = 57) based on criteria used to select patients for capecitabine/RT. We also created a matched cohort (2:1), matching on tumor subtype, pathological stage and age (< 50 or 50+ years). Differences in EFS, using STEEP criteria, and OS, using all-cause mortality, between those who received capecitabine/RT and controls were assessed. RESULTS: Of the 21 women who received capecitabine/RT, median age was 52 years. The majority were pathologic stage III (n = 15) and hormone receptor-positive/HER2-negative BC (n = 20). In those receiving capecitabine/RT, there were 9 events, compared with 14 events in clinical and 10 events in matched controls. Capecitabine/RT was associated with worse OS in clinical (HR 3.83 95% CI 1.12-13.11, p = 0.03) and matched controls (HR 3.71 95% CI 1.04-13.18, p = 0.04), after adjusting for clinical size, pathological stage and lymphovascular invasion. Capecitabine/RT was also associated with a trend towards worse EFS in clinical (HR 2.41 95% CI 0.86-6.74, p = 0.09) and matched controls (HR 2.68 95% CI 0.91-7.90, p = 0.07) after adjustment. CONCLUSION: Concurrent capecitabine/RT after NAC is associated with worse survival and should be carefully considered in BC.


Asunto(s)
Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/radioterapia , Quimioradioterapia Adyuvante/métodos , Adulto , Anciano , Neoplasias de la Mama/mortalidad , Capecitabina/administración & dosificación , Quimioradioterapia Adyuvante/mortalidad , Supervivencia sin Enfermedad , Femenino , Humanos , Estimación de Kaplan-Meier , Persona de Mediana Edad , Terapia Neoadyuvante/métodos , Modelos de Riesgos Proporcionales , Estudios Retrospectivos , Resultado del Tratamiento
2.
Kidney Blood Press Res ; 41(5): 535-544, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27561821

RESUMEN

BACKGROUND/AIMS: Hyponatremia associated with high urinary fractional excretion of uric acid which persists after serum sodium is corrected is the cardinal feature of salt losing nephropathy (SLN). We hypothesize that low grade proximal tubular injury is present in SLN because the proximal tubule is the main site of uric acid and sodium transport. METHODS: Five subjects with SLN were compared to four subjects with recurrent hyponatremia and three healthy individuals. Urinary NGAL (neutrophil gelatinase associated lipocalin, a marker of tubular injury) and fasting urinary fructose levels (a marker of proximal tubular injury) were measured. RESULTS: Subjects with SLN (n=5) showed elevated fractional uric acid excretion (22 ± 6 vs 4 ± 2 percent, p<0.0001), elevated urinary NGAL levels (62 ± 37 vs 9 ± 7 ng/mg creatinine, p=0.001) and fasting urinary fructose levels compared with the 7 controls (383 ± 465 vs 60 ± 34µmole/µg creatinine, p <0.001). A strong correlation between urinary NGAL levels and urinary fructose levels was observed (r =0.87, p<0.001). CONCLUSION: High urinary fractional excretion of uric acid in SLN is associated with elevated NGAL and fasting urinary fructose levels suggesting that SLN may involve tubular injury.


Asunto(s)
Hiponatremia/orina , Túbulos Renales Proximales/lesiones , Ácido Úrico/orina , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Fructosa/orina , Humanos , Enfermedades Renales , Lipocalina 2/orina , Masculino , Persona de Mediana Edad , Sodio/sangre , Adulto Joven
4.
J Chem Ecol ; 12(5): 1157-70, 1986 May.
Artículo en Inglés | MEDLINE | ID: mdl-24307053

RESUMEN

The majority (85%) of 394 monarch butterflies sampled from overwintering sites in Mexico contain the same epoxy cardenolide glycosides, including most conspicuously a novel polar glycoside with a single genin-sugar bridge (aspecioside), as occur in the milkweedsAsclepias speciosa andA. syriaca. This cardenolide commonality was established by isolating aspecioside and syriobioside from the wings of overwintering monarchs and the two plant species, and comparing Chromatographie and NMR spectrometric characteristics of the isolates. When combined with the migratory pattern of monarchs and the distribution of these two milkweed species, this chemical evidence lends strong support to the hypothesis thatA. syriaca is the major late summer food plant of monarchs in eastern North America. This finding may be of ecological importance, forA. syriaca contributes less cardenolide and cardenolides of lower emetic potency to monarchs than most milkweeds studied to date.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA